Dermatological Drugs - Puerto Rico

Puerto Rico

The Dermatological Drugs market in Puerto Rico is anticipated to witness a significant growth in revenue, with projections indicating a substantial increase to reach US$6.84m by the year 2024.
This growth is expected to continue at an annual growth rate of 5.31% from 2024 to 2029, resulting in a market volume of US$8.86m by the end of the forecast period.
In comparison to other countries, United States is expected to generate the highest revenue in the Dermatological Drugs market, with an estimated value of US$11,670.00m in 2024.
Puerto Rico has seen a rising demand for dermatological drugs due to its high levels of sun exposure and prevalence of skin conditions.

Key regions: United Kingdom, Canada, Japan, Europe, China

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for dermatological drugs in Puerto Rico has been on the rise in recent years.

Customer preferences: Puerto Ricans have become increasingly concerned about skincare, leading to a surge in demand for dermatological drugs. The population has a high prevalence of skin conditions such as acne, eczema, and psoriasis, which has further fueled the demand for dermatological drugs.

Trends in the market: The dermatological drugs market in Puerto Rico has been growing due to the increasing prevalence of skin diseases and the aging population. The market is dominated by topical drugs, which are preferred by patients due to their ease of use and non-invasive nature. There has also been a shift towards natural and organic products, as consumers become more health-conscious and environmentally aware.

Local special circumstances: Puerto Rico's tropical climate and high humidity levels make it a conducive environment for skin diseases. The island's population is also diverse, with a mix of Hispanic, African, and European ancestry, leading to a wide range of skin types and conditions. The island's healthcare system is also heavily influenced by the United States, with many American pharmaceutical companies operating in Puerto Rico.

Underlying macroeconomic factors: Puerto Rico's economy has been struggling in recent years, with high unemployment rates and a significant debt crisis. However, the healthcare sector has remained relatively stable, with the government investing in healthcare infrastructure and services. The island's status as a US territory also provides access to US markets and resources, which has helped to attract foreign investment in the pharmaceutical industry.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.